Sitryx: Sitryx licenses intellectual property rights for inhibitors of a new target in immunometabolism from Cancer Research UK in exclusive worldwide agreement

(marketscreener.com) Sitryx licenses intellectual property rights for inhibitors of a new target in immunometabolism from Cancer Research UK in exclusive worldwide agreement Oxford, UK - 6 July 2021 - Sitryx , a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-inflammation and...https://www.marketscreener.com/news/latest/Sitryx-licenses-intellectual-property-rights-for-inhibitors-of-a-new-target-in-immunometabolism-from--35794831/?utm_medium=RSS&utm_content=20210706